Publications
5491 Results
- Journal / Conference
- Ann Surg Oncol. Mar;30(3):1302-1304
- Year
- 2023
- Research Committee(s)
- Gastrointestinal
- PMID
- PMID36474095
- Study Number(s)
- S2104
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors [Research Letter]
- Journal / Conference
- Proceedings Society of Hematologic Oncology 2023 Annual Meeting; Lymphoma, Myeloma & Leukemia Vol 23 Suppl 1S1-S593, poster
- Year
- 2023
- Research Committee(s)
- Myeloma
- Study Number(s)
- S0777
Adjusted Indirect Treatment Comparison of Progression-Free Survival Associated With D-Rd and VRd Based on MAIA and SWOG S0777 Individual Patient-Level Data
- Journal / Conference
- AACR Annual Meeting (April 14-19, 2023, Orlando, FL, poster
- Year
- 2023
- Research Committee(s)
- Early Therapeutics and Rare Cancers
- Study Number(s)
- S1609
A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: The clear cell gynecologic cancer cohorts #42, 45, 46
- Journal / Conference
- AACR Annual Meeting (April 14-19, 2023, Orlando, FL, oral
- Year
- 2023
- Research Committee(s)
- Melanoma
- Study Number(s)
- S1512
S1512: High response rate with single agent anti-PD-1 in patients with metastatic desmoplastic melanoma
- Journal / Conference
- Cancer Research Communications Sep 28 3(9):1959-1965. doi:10.1158/2767-9764.CRC-23-0255
- Year
- 2023
- Research Committee(s)
- Cancer Care Delivery
- PMID
- PMID37707388
- PMC
- PMC10541082
- Study Number(s)
- S1204
Universal Viral Screening of Newly Diagnosed Cancer Patients in the United States: A Cost Efficiency Evaluation
- Journal / Conference
- J Clin Oncol 41, 2023 (suppl 6; abstr TPS581); ASCO GU Cancers Symposium (Feb 16-18, 2023, San Francisco, CA), poster
- Year
- 2023
- Research Committee(s)
- Genitourinary
- Study Number(s)
- S1937
A Phase III Randomized Trial of Eribulin (E) with or without gemcitabine vs Standard of Care (SOC) for Metastatic Urothelial Carcinoma (UC) Refractory to or ineligible for PD/PDL1 Antibody (Ab): SWOG S1937 (ClicalTrials.gov NCT04579224)
- Journal / Conference
- J Clin Oncol 41, 2023 (suppl 4; abstr TPS784); ASCO GI Cancers Symposium (January 19-21, 2023, San Francisco, CA), TIP poster
- Year
- 2023
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- S1922
Randomized, Phase II Selection Study of Ramucirumab and Paclitaxel versus FOLFIRI in Refractory Small Bowel Adenocarcinoma: SWOG S1922
- Journal / Conference
- Annals of Oncology VOLUME 34, SUPPLEMENT 1, S96, JUNE 2023; ESMO World Congress on Gastrointestinal Cancer (6/28/2023 - 7/1/2023, Barcelona, Spain) TIP poster
- Year
- 2023
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- S2107
SWOG S2107: Randomized phase II trial of encorafenib and cetuximab with or without nivolumab for patients with previously treated, microsatellite stable, BRAFV600E metastatic and/or unresectable colorectal cancer
- Journal / Conference
- Ann Oncol. Apr;34(4):397-409
- Year
- 2023
- Research Committee(s)
- Breast
- PMID
- PMID36709040
Genomic characterisation of hormone receptor-positive breast cancer arising in very young women
- Journal / Conference
- Cancers Aug 3;15(15):3949
- Year
- 2023
- Research Committee(s)
- Breast
- PMID
- PMID37568766
- PMC
- PMC10417732
- Study Number(s)
- S1222, S1416